Piramal Pharma, 543635, PPLPHARMA Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

25,169.31
256.65
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

29,388.12
0.07%
3.16

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
7.70
8.92

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-0.14
17.68

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-35.79
115.07

P:E (Median)

8 Years
5 Years
3 Years

-
-
22.68

P:BV (Average)

8 Years
5 Years
3 Years

-
-
2.67

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
56.71

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 0.14 0.69 1.77 4.87
P/E Ratio 1352.93 274.51 107.01 38.89
Revenue 8106 9151 9887 11658
EBITDA 1196 1445 1552 2185
Net Income 18 91 223 630
ROA 0.1 0.6
P/B Ratio 3.73 3.69 2.96 2.75
ROE 0.24 1.24 2.81 7.22
FCFF -147 -164 492 628
FCFF Yield -0.47 -0.52 1.57 2.01
Net Debt 4083 4335 4000 3723
BVPS 50.74 51.3 64.03 68.89

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 969.88 1,063.20 -8.78% 1,689.80 1,525.30 10.78% 1,248.32 1,024.14 21.89% 1,284.39 994.24 29.18%
Expenses 925.55 911.57 1.53% 1,273.22 1,135.66 12.11% 1,028.98 898.61 14.51% 1,031.50 908.08 13.59%
EBITDA 44.33 151.63 -70.76% 416.58 389.64 6.91% 219.34 125.53 74.73% 252.89 86.16 193.51%
EBIDTM 4.57% 14.26% 24.65% 25.55% 17.57% 12.26% 19.69% 8.67%
Other Income 180.92 36.76 392.17% 39.51 53.19 -25.72% 24.70 33.11 -25.40% 106.38 89.08 19.42%
Interest 23.23 24.88 -6.63% 30.56 27.66 10.48% 29.17 17.42 67.45% 29.95 28.22 6.13%
Depreciation 59.44 51.85 14.64% 61.17 52.50 16.51% 55.46 51.56 7.56% 53.61 50.83 5.47%
PBT 142.58 111.66 27.69% 364.36 362.67 0.47% 159.41 89.66 77.79% 275.71 96.19 186.63%
Tax 29.44 26.39 11.56% 87.09 89.59 -2.79% 40.61 15.32 165.08% 65.65 19.03 244.98%
PAT 113.14 85.27 32.68% 277.27 273.08 1.53% 118.80 74.34 59.81% 210.06 77.16 172.24%
PATM 11.67% 8.02% 16.41% 17.90% 9.52% 7.26% 16.35% 7.76%
EPS 0.85 0.64 32.81% 2.09 2.05 1.95% 0.89 0.56 58.93% 1.58 0.58 172.41%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,933.71 1,951.14 -0.89% 2,754.07 2,552.36 7.90% 2,204.22 1,958.57 12.54% 2,241.75 1,911.38 17.28%
Expenses 1,827.01 1,746.65 4.60% 2,193.08 2,022.43 8.44% 1,866.48 1,690.20 10.43% 1,900.14 1,645.74 15.46%
EBITDA 106.70 204.49 -47.82% 560.99 529.93 5.86% 337.74 268.37 25.85% 341.61 265.64 28.60%
EBIDTM 5.52% 10.48% 20.37% 20.76% 15.32% 13.70% 15.24% 13.90%
Other Income 58.40 19.54 198.87% 42.03 26.38 59.33% 12.13 61.51 -80.28% 61.11 49.19 24.23%
Interest 86.15 106.96 -19.46% 103.68 114.22 -9.23% 103.31 105.88 -2.43% 107.64 109.87 -2.03%
Depreciation 197.28 184.55 6.90% 242.76 196.13 23.78% 196.81 186.32 5.63% 192.22 184.51 4.18%
PBT -97.59 -67.48 - 256.58 215.44 19.10% 49.75 5.41 819.59% 102.86 20.45 402.98%
Tax 2.68 43.56 -93.85% 119.30 126.21 -5.48% 63.12 9.25 582.38% 97.53 34.54 182.37%
PAT -100.27 -111.04 - 137.28 89.23 53.85% -13.37 -3.84 - 5.33 -14.09 -
PATM -5.19% -5.69% 4.98% 3.50% -0.61% -0.20% 0.24% -0.74%
EPS -0.62 -0.67 - 1.16 0.77 50.65% 0.03 0.08 -62.50% 0.17 0.04 325.00%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 5,192.39 5,285.71 4,390.11 3,443.22 3,340.42 2,938.81 Net Sales Growth 12.71% 20.40% 27.50% 3.08% 13.67% Cost Of Goods Sold 2,222.27 2,245.96 2,108.84 1,768.48 1,561.51 1,227.77 Gross Profit 2,970.12 3,039.75 2,281.27 1,674.74 1,778.91 1,711.04 GP Margin 57.20% 57.51% 51.96% 48.64% 53.25% 58.22% Total Expenditure 4,259.25 4,276.55 3,790.71 3,345.69 2,865.14 2,319.88 Power & Fuel Cost - 131.62 112.89 107.94 83.83 68.08 % Of Sales - 2.49% 2.57% 3.13% 2.51% 2.32% Employee Cost - 736.19 613.93 548.50 448.03 395.15 % Of Sales - 13.93% 13.98% 15.93% 13.41% 13.45% Manufacturing Exp. - 356.88 317.98 318.40 283.52 246.85 % Of Sales - 6.75% 7.24% 9.25% 8.49% 8.40% General & Admin Exp. - 420.18 341.84 310.59 261.25 209.20 % Of Sales - 7.95% 7.79% 9.02% 7.82% 7.12% Selling & Distn. Exp. - 253.98 212.89 230.60 182.88 135.62 % Of Sales - 4.81% 4.85% 6.70% 5.47% 4.61% Miscellaneous Exp. - 131.74 82.34 61.18 44.12 37.21 % Of Sales - 2.49% 1.88% 1.78% 1.32% 1.27% EBITDA 933.14 1,009.16 599.40 97.53 475.28 618.93 EBITDA Margin 17.97% 19.09% 13.65% 2.83% 14.23% 21.06% Other Income 351.51 238.63 220.58 341.07 224.79 197.97 Interest 112.91 114.56 107.10 115.87 57.29 4.71 Depreciation 229.68 222.09 205.26 192.08 165.37 143.64 PBT 942.06 911.14 507.62 130.65 477.41 668.55 Tax 222.79 219.74 116.40 54.19 94.79 115.28 Tax Rate 23.65% 24.12% 22.93% 43.81% 20.50% 16.79% PAT 719.27 691.40 391.22 69.50 367.54 571.50 PAT before Minority Interest 719.27 691.40 391.22 69.50 367.54 571.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.85% 13.08% 8.91% 2.02% 11.00% 19.45% PAT Growth 41.07% 76.73% 462.91% -81.09% -35.69% EPS 5.41 5.20 2.94 0.52 2.77 4.30

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 9,133.75 9,151.18 8,171.16 7,081.55 6,559.10 6,314.90 Net Sales Growth 9.08% 11.99% 15.39% 7.97% 3.87% Cost Of Goods Sold 3,251.33 3,231.65 2,954.00 2,703.30 2,451.26 2,059.11 Gross Profit 5,882.42 5,919.53 5,217.16 4,378.25 4,107.84 4,255.79 GP Margin 64.40% 64.69% 63.85% 61.83% 62.63% 67.39% Total Expenditure 7,786.71 7,733.31 7,000.65 6,453.31 5,609.44 4,886.94 Power & Fuel Cost - 267.16 241.59 207.81 163.56 136.70 % Of Sales - 2.92% 2.96% 2.93% 2.49% 2.16% Employee Cost - 2,307.47 2,029.50 1,896.35 1,588.83 1,467.74 % Of Sales - 25.21% 24.84% 26.78% 24.22% 23.24% Manufacturing Exp. - 774.18 731.64 674.10 589.03 544.09 % Of Sales - 8.46% 8.95% 9.52% 8.98% 8.62% General & Admin Exp. - 563.04 542.00 472.78 428.49 367.25 % Of Sales - 6.15% 6.63% 6.68% 6.53% 5.82% Selling & Distn. Exp. - 398.11 359.75 372.59 317.81 247.91 % Of Sales - 4.35% 4.40% 5.26% 4.85% 3.93% Miscellaneous Exp. - 191.70 142.17 126.38 70.46 64.14 % Of Sales - 2.09% 1.74% 1.78% 1.07% 1.02% EBITDA 1,347.04 1,417.87 1,170.51 628.24 949.66 1,427.96 EBITDA Margin 14.75% 15.49% 14.32% 8.87% 14.48% 22.61% Other Income 173.67 161.77 201.14 225.11 275.80 164.11 Interest 400.78 421.59 448.49 344.18 198.25 163.45 Depreciation 829.07 816.34 740.57 676.69 586.18 545.04 PBT 311.60 341.71 182.59 -167.52 441.03 883.58 Tax 282.63 323.51 161.47 66.31 109.02 114.02 Tax Rate 90.70% 94.67% 134.78% -38.00% 25.59% 12.64% PAT 28.97 91.13 17.82 -186.46 375.96 835.03 PAT before Minority Interest 28.97 91.13 17.82 -186.46 375.96 835.03 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 0.32% 1.00% 0.22% -2.63% 5.73% 13.22% PAT Growth 172.90% 411.39% - - -54.98% EPS 0.22 0.69 0.13 -1.40 2.83 6.28

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 7,452.54 6,712.07 5,261.79 5,123.12 4,100.62 Share Capital 1,324.35 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,064.63 5,361.65 4,068.47 3,937.21 3,105.92 Non-Current Liabilities 1,199.34 859.80 1,083.17 800.72 184.38 Secured Loans 356.84 363.94 592.34 477.12 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 615.10 281.04 274.43 143.85 6.59 Current Liabilities 2,306.49 2,307.35 1,951.29 1,655.39 1,566.96 Trade Payables 1,184.76 1,107.71 761.67 646.80 584.12 Other Current Liabilities 426.66 503.64 430.07 488.22 681.78 Short Term Borrowings 652.22 531.64 720.34 390.21 165.20 Short Term Provisions 42.85 164.36 39.21 130.16 135.86 Total Liabilities 10,958.37 9,879.22 8,296.25 7,579.23 5,851.96 Net Block 2,894.28 2,612.16 2,601.87 2,438.98 1,626.81 Gross Block 4,258.04 3,766.97 3,564.57 3,225.28 2,260.11 Accumulated Depreciation 1,363.76 1,154.81 962.70 786.30 633.30 Non Current Assets 7,422.49 6,508.14 5,947.57 5,400.24 3,989.17 Capital Work in Progress 327.30 533.24 416.57 405.16 121.00 Non Current Investment 3,105.31 1,646.88 1,646.87 1,592.52 1,591.52 Long Term Loans & Adv. 1,095.60 1,715.86 1,282.22 963.54 649.84 Other Non Current Assets 0.00 0.00 0.04 0.04 0.00 Current Assets 3,535.88 3,371.08 2,348.68 2,178.99 1,862.79 Current Investments 0.00 61.28 100.12 37.01 0.00 Inventories 1,205.35 1,153.04 818.61 535.51 420.88 Sundry Debtors 1,666.69 1,331.38 909.56 989.22 839.75 Cash & Bank 177.84 241.73 64.16 137.23 152.35 Other Current Assets 486.00 60.24 28.98 39.00 449.81 Short Term Loans & Adv. 369.13 523.41 427.25 441.02 405.31 Net Current Assets 1,229.39 1,063.73 397.39 523.60 295.83 Total Assets 10,958.37 9,879.22 8,296.25 7,579.23 5,851.96

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 8,125.47 7,911.37 6,773.50 6,696.60 5,605.00 Share Capital 1,324.35 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,738.96 6,560.95 5,580.18 5,510.69 4,610.30 Non-Current Liabilities 3,392.72 2,644.64 3,812.00 2,902.58 2,560.38 Secured Loans 3,214.07 2,483.75 3,383.54 2,622.14 2,339.16 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 48.66 32.32 275.97 145.34 6.78 Current Liabilities 3,766.27 4,369.30 3,851.04 3,118.01 2,590.70 Trade Payables 1,533.77 1,538.37 1,192.71 1,026.35 917.94 Other Current Liabilities 1,184.72 1,575.68 1,305.30 1,242.76 1,140.63 Short Term Borrowings 995.32 1,171.38 1,302.29 658.76 360.52 Short Term Provisions 52.46 83.87 50.74 190.14 171.61 Total Liabilities 15,284.46 14,925.31 14,436.54 12,717.19 10,756.08 Net Block 8,133.43 7,989.93 7,468.60 6,879.18 6,105.49 Gross Block 13,117.63 12,137.48 10,842.12 9,510.49 8,173.25 Accumulated Depreciation 4,984.20 4,147.55 3,373.52 2,631.31 2,067.76 Non Current Assets 9,487.47 9,460.84 9,593.07 8,565.30 7,006.96 Capital Work in Progress 976.90 1,115.80 1,418.58 1,172.34 626.65 Non Current Investment 271.09 240.26 211.87 216.77 122.67 Long Term Loans & Adv. 91.08 114.85 493.98 296.97 152.11 Other Non Current Assets 14.97 0.00 0.04 0.04 0.04 Current Assets 5,796.99 5,464.47 4,843.47 4,151.89 3,749.12 Current Investments 19.56 144.69 427.11 50.40 0.00 Inventories 2,312.70 2,175.88 1,681.37 1,388.80 1,232.00 Sundry Debtors 2,349.52 2,134.43 1,799.34 1,785.28 1,574.94 Cash & Bank 501.46 482.56 307.56 328.99 405.62 Other Current Assets 613.75 81.93 140.24 93.66 536.56 Short Term Loans & Adv. 478.88 444.98 487.85 504.76 395.55 Net Current Assets 2,030.72 1,095.17 992.43 1,033.88 1,158.42 Total Assets 15,284.46 14,925.31 14,436.54 12,717.19 10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 548.77 358.29 71.52 249.19 34.72 PBT 911.14 507.62 123.69 477.41 349.11 Adjustment 264.51 221.26 50.70 42.92 8.96 Changes in Working Capital -392.59 -292.78 -42.84 -168.48 -228.06 Cash after chg. in Working capital 783.06 436.10 131.55 351.85 130.01 Interest Paid 0.00 0.00 0.00 0.00 0.00 Tax Paid -234.29 -77.81 -60.03 -102.66 -95.29 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -549.98 -635.52 -435.05 -1,245.61 -4,382.89 Net Fixed Assets -285.13 -319.07 -350.70 -1,249.33 Net Investments -1,397.15 38.83 -117.46 -38.01 Others 1,132.30 -355.28 33.11 41.73 Cash from Financing Activity -61.74 451.38 290.12 896.40 4,494.16 Net Cash Inflow / Outflow -62.95 174.15 -73.41 -100.02 145.99 Opening Cash & Equivalents 228.80 54.28 127.69 146.72 0.74 Closing Cash & Equivalent 163.87 228.80 54.28 127.69 146.73

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 892.30 1,004.54 483.89 766.42 597.58 PBT 341.71 119.80 -160.56 441.03 639.68 Adjustment 1,372.66 1,275.88 1,135.53 787.10 721.99 Changes in Working Capital -487.72 -234.30 -302.08 -292.29 -619.58 Cash after chg. in Working capital 1,226.65 1,161.38 672.89 935.84 742.09 Interest Paid 0.00 0.00 0.00 0.00 0.00 Tax Paid -334.35 -156.84 -189.00 -169.42 -144.51 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -477.46 -434.01 -1,338.78 -1,812.10 -4,479.93 Net Fixed Assets -285.13 -319.07 -350.70 -1,249.33 Net Investments -1,397.15 38.83 -117.46 -38.01 Others 1,204.82 -153.77 -870.62 -524.76 Cash from Financing Activity -440.83 -422.36 817.79 794.19 3,976.83 Net Cash Inflow / Outflow -25.99 148.17 -37.10 -251.49 94.48 Opening Cash & Equivalents 219.19 53.23 85.18 261.97 151.95 Closing Cash & Equivalent 182.32 219.19 53.23 85.18 261.97

Financial Ratios

Standalone /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 55.79 50.53 43.06 42.19 41.23 ROA 6.64% 4.30% 0.88% 5.47% 9.77% ROE 9.83% 6.55% 1.34% 7.97% 13.94% ROCE 12.40% 8.33% 3.64% 9.86% 16.21% Fixed Asset Turnover 1.36 1.26 1.05 1.24 1.30 Receivable days 100.49 88.86 96.97 98.40 104.30 Inventory Days 79.05 78.18 69.15 51.45 52.27 Payable days 186.28 161.78 145.35 143.86 173.65 Cash Conversion Cycle -6.74 5.26 20.77 5.99 -17.08 Total Debt/Equity 0.17 0.17 0.31 0.23 0.04 Interest Cover 8.95 5.74 2.07 9.07 146.81

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 60.88 59.59 55.44 55.15 56.35 ROA 0.60% 0.12% -1.37% 3.20% 7.76% ROE 1.14% 0.24% -2.77% 6.11% 14.90% ROCE 6.61% 5.07% 1.95% 7.10% 13.06% Fixed Asset Turnover 0.84 0.82 0.80 0.83 0.77 Receivable days 77.05 76.20 80.70 83.94 91.03 Inventory Days 77.13 74.72 69.11 65.47 71.21 Payable days 173.49 168.73 149.81 144.76 162.72 Cash Conversion Cycle -19.30 -17.80 0.00 4.65 -0.47 Total Debt/Equity 0.59 0.58 0.81 0.60 0.52 Interest Cover 1.98 1.40 0.65 3.45 6.81

Top Investors:

ca alchemy investments

hdfc trustee company limited-hdfc flexi cap fund

east bridge capital master fund i ltd

indiahold limited

canara robeco mutual fund a/c canara robeco small cap fund

llp

investor education and protection fund (iepf)

Annual Reports:

News Update:

Piramal Pharma reports consolidated net loss of Rs 81.70 crore in Q1
29th Jul 2025, 12:30 PM

The consolidated total income of the company increased by 1.09% at Rs 1992.11 crore for Q1FY26
Read More
USFDA concludes GMP inspection at Piramal Pharma’s Canada facility
2nd Jun 2025, 15:14 PM

The inspection was completed successfully with Zero Form - 483 observations
Read More
Piramal Pharma reports 51.57% rise in Q4 consolidated net profit
15th May 2025, 12:30 PM

The total consolidated income of the company increased by 8.43% at Rs 2,796.10 crore for Q4FY25
Read More
Piramal Pharma receives EIR from USFDA for Turbhe facility
12th May 2025, 12:12 PM

The company has received the EIR for its Turbhe facility
Read More

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543635 | NSE: PPLPHARMA

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: